Compare SIEB & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SIEB | NMRA |
|---|---|---|
| Founded | 1886 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 87.4M |
| IPO Year | 1996 | 2023 |
| Metric | SIEB | NMRA |
|---|---|---|
| Price | $1.83 | $0.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 13.8K | ★ 2.1M |
| Earning Date | 11-20-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $94,202,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.28 | N/A |
| 52 Week Low | $1.53 | $0.32 |
| 52 Week High | $4.14 | $3.65 |
| Indicator | SIEB | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 38.19 | 45.79 |
| Support Level | $1.72 | $0.33 |
| Resistance Level | $2.01 | $1.74 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 17.62 | 44.64 |
Siebert Financial Corp is a diversified financial services firm engaged in providing brokerage and financial advisory services. The coperates through two segments: Financial Services and Media, Sports and Entertainment. The Financial Services segment mainly operates as a securities broker-dealer and provides brokerage, custody, and clearing services for retail accounts, as well as insurance and advisory services, principal and proprietary trading, market making, securities lending, and investment banking and capital markets services. The Media, Sports and Entertainment segment is engaged in the production and distribution of music and media content, as well as talent management and sports representation. It generates the majority of its revenue from the Financial Services segment.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.